Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Exscientia plc

Exscientia Business Update for First Quarter 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors
From Exscientia plc
Via Business Wire
Tickers EXAI
Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Report Full Year 2022 Financial Results on March 23, 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Announces Expansion of its Precision Oncology Pipeline
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present at Upcoming Investor Conferences in March
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business and Financial Update for the Third Quarter 2022
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Expands Biologics Design Capability with Automated Laboratory
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Welcomes Caroline Rowland as Chief People Officer
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business Update for Second Quarter and First Half 2022
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business Update for First Quarter 2022
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the American Association of Cancer Research Annual Meeting 2022
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business Update for Fourth Quarter and Full Year 2021
From Exscientia plc
Via Business Wire
Tickers EXAI
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.